Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/95347
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pfahler, Vanessa | - |
dc.contributor.author | D'Anastasi, Melvin | - |
dc.contributor.author | Dürr, Hans-Roland | - |
dc.contributor.author | Schinner, Regina | - |
dc.contributor.author | Ricke, Jens | - |
dc.contributor.author | Baur-Melnyk, Andrea | - |
dc.date.accessioned | 2022-05-10T04:56:13Z | - |
dc.date.available | 2022-05-10T04:56:13Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Pfahler, V., D'Anastasi, M., Dürr, H. R., Schinner, R., Ricke, J., & Baur‐Melnyk, A. (2020). Tumor load in patients with multiple myeloma: β₂‐microglobulin levels versus low‐dose whole‐body CT. European Journal of Haematology, 104(5), 383-389. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/95347 | - |
dc.description.abstract | Objective: Beta-2-microglobulin is a serum marker of tumor burden in multiple myeloma (MM). Our aim was to correlate serum β₂-microglobulin levels in patients with MM to tumor burden determined by low-dose whole-body CT (LDWBCT). Materials and Methods: A total of 52 patients with newly diagnosed, untreated MM who underwent LDWBCT were included. LDWBCT scans were assessed by two musculoskeletal radiologists in consensus for focal lesions. The Durie and Salmon PLUS staging system was used for staging patients in stages I-III. β₂-microglobulin was also subdivided into stages I-III on the basis of the multiple myeloma International Staging System (ISS). | en_GB |
dc.description.abstract | Results: Using the Durie and Salmon PLUS staging system criteria for image evaluation, we were able to identify stage I MM in 17 patients, stage II MM in nine patients, and stage III MM in 26 patients. Eight of nine patients with stage II MM and 16 of 26 patients with stage III MM had normal β₂-microglobulin levels. Thus, 24 of 35 patients (68.6%) had 5 or more focal lesions and false-negative β₂-microglobulin levels. | en_GB |
dc.description.abstract | Conclusion: Serum β₂-microglobulin levels alone may not indicate the full extent of tumor burden in a significant subset of myeloma patients. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Wiley | en_GB |
dc.rights | info:eu-repo/semantics/restrictedAccess | en_GB |
dc.subject | Beta 2-Microglobulin | en_GB |
dc.subject | Tumor markers -- Diagnostic use | en_GB |
dc.subject | Magnetic resonance imaging -- Case studies | en_GB |
dc.subject | Multiple myeloma -- Diagnosis | en_GB |
dc.subject | Neoplasms, plasma cell | en_GB |
dc.title | Tumor load in patients with multiple myeloma : β₂‐microglobulin levels versus low‐dose whole‐body CT | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.1111/ejh.13356 | - |
dc.publication.title | European Journal of Haematology | en_GB |
Appears in Collections: | Scholarly Works - FacM&SCRNM |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Tumor_load_in_patients_with_multiple_myeloma_B2_microglobulin_levels_versus_low_dose _whole_body_CT_2020.pdf Restricted Access | 1.59 MB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.